{"filing":{"accession_number":"0001193125-26-254476","cik":"0001676725","ticker":"IDYA","company_name":"IDEAYA Biosciences, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"d53214d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526254476/d53214d8k.htm"},"events":[{"id":7125,"run_id":6251,"accession_number":"0001193125-26-254476","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"IDEAYA announced a clinical collaboration with Roche to evaluate IDE892 (PRMT5 inhibitor) in combination with RG6505 (pan-RAS inhibitor) in MTAP-deleted pancreatic cancer. This represents a material strategic partnership with a major pharmaceutical company that advances the Company's clinical development pipeline and validates its lead compound in a combination setting. While this does not fit neatly into the more specific event categories (it is not M\u0026A, litigation, impairment, or a traditional earnings/executive event), the collaboration with Roche and the planned Phase 1 combination cohorts constitute material developments affecting the Company's business prospects and investor assessment.","company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":3922,"accession_number":"0001193125-26-254476","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"IDEAYA announced a clinical collaboration with Roche to evaluate IDE892 (PRMT5 inhibitor) in combination with RG6505 (pan-RAS inhibitor) in MTAP-deleted pancreatic cancer. This represents a material strategic partnership with a major pharmaceutical company that advances the Company's clinical development pipeline and validates its lead compound in a combination setting. While this does not fit neatly into the more specific event categories (it is not M\u0026A, litigation, impairment, or a traditional earnings/executive event), the collaboration with Roche and the planned Phase 1 combination cohorts constitute material developments affecting the Company's business prospects and investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:20:54.784032+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3922,"accession_number":"0001193125-26-254476","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"IDEAYA announced a clinical collaboration with Roche to evaluate IDE892 (PRMT5 inhibitor) in combination with RG6505 (pan-RAS inhibitor) in MTAP-deleted pancreatic cancer. This represents a material strategic partnership with a major pharmaceutical company that advances the Company's clinical development pipeline and validates its lead compound in a combination setting. While this does not fit neatly into the more specific event categories (it is not M\u0026A, litigation, impairment, or a traditional earnings/executive event), the collaboration with Roche and the planned Phase 1 combination cohorts constitute material developments affecting the Company's business prospects and investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:20:54.784032+00:00","company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","filing_date":"2026-06-03"}]}